Pronota awarded EUR 1.4 million grant to validate and develop novel cardiovascular biomarkers

14-Jan-2010 - Belgium

Pronota NV has announced that it has been awarded an EUR 1.4 million grant from IWT (the Institute for the Promotion of Innovation by Science and Technology in Flanders) to further validate and develop novel biomarkers for the management of heart failure.

The grant will be used to validate and biologically characterize in great detail novel candidate protein markers discovered using Pronota’s proprietary MASStermindTM platform. In addition, the grant supports the development of generic immuno-based assays for the lead candidates, which will be used for the final clinical validation in a large, multicenter, clinical trial and the regulatory submission.

Commenting on the grant, Dr Koen Kas, founder and CSO of Pronota said: "This award, which follows on the heels of the 2009 series B fundraising, totaling EUR 6.4 million, provides us with the means to address a significant clinical and commercial opportunity which should prove the era of clinical proteomics has finally arrived”.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances